Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Reimbursement News › Myriad Genetics Melanoma Test Gets Final LCD

Myriad Genetics Melanoma Test Gets Final LCD

Mar 14, 2019
|
staff reporter

NEW YORK (GenomeWeb)  — Medicare contractor Palmetto GBA has issued a final local coverage determination (LCD) for Myriad Genetics' myPath Melanoma test, the firm announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

What's Popular?

In Molecular Diagnostics

  1. COVID-19 Testing Plays Into Abbott's Long-Term Diagnostic Strategy

    Premium

  2. FDA Grants EUAs for Wren Labs, P23 Coronavirus Tests, Binx Health At-Home Sample Collection Kit

  3. Thermo Fisher Scientific Continues to See Strong Demand for Pandemic-Related Products and Services

    Premium

  4. BD, CerTest Biotec Get CE-IVD Mark for Combination COVID-19, Influenza, RSV Test on BD Max

  5. FDA Reissues Emergency Use Authorization for Thermo Fisher Scientific COVID-19 Combo Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.